Kristopher P Croome1,2, Shennen A Mao1, Jaime M Glorioso1, Murli Krishna3, Scott L Nyberg4, David M Nagorney1. 1. Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN, USA. 2. Department of Transplantation, Mayo Clinic Florida, Jacksonville, FL, USA. 3. Division of Pathology, Mayo Clinic, Jacksonville, FL, USA. 4. Division of Transplantation Surgery and Mayo Clinic William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Publications using the ALPPS (associating liver partition and portal vein ligation for a staged hepatectomy) procedure have demonstrated a future liver remnant growth of 40-160% in only 6-9 days. The present study aimed to develop and describe the first large animal model of ALPPS that can be used for future studies. METHODS: A total of 13 female domestic pigs underwent ALPPS stage 1 (portal vein division and parenchymal transection) followed by ALPPS stage 2 (completion left-extended hepatectomy) 7 days later. An abdominal computed tomography (CT) scan was performed immediately prior to ALPPS stage 1 surgery and again 7 days later to assess hypertrophy immediately prior to ALPPS stage 2 surgery. Blood samples, as well as tissue analysis for Ki-67, were performed. RESULTS: On CT volumetric analysis, the mean size of the future liver remnant (FLR) prior to ALPPS stage 1 was 21 ± 2% and 40 ± 6% prior to ALPPS stage 2. The median degree of growth was 75% with a mean kinetic growth rate of 11% per day. Liver weights at autopsy correlated well with CT volumetric analysis (r = 0.87). There was no significant difference in mean lab values [asparate aminotransferase (AST), alanine aminotransferase (ALT), ammonia, International Normalized Ratio (INR) or bilirubin] from baseline until immediately prior to ALPPS stage 2. Post ALPPS stage 2 there was a significant increase in INR from baseline 1.1 to 1.6 (P = 0.012). No post-operative deaths secondary to liver failure were observed. CONCLUSION: The present study describes the first reproducible large animal model of the ALPPS procedure. The degree of liver growth and the kinetic rate of growth were similar to that which has been demonstrated in human publications. This model will be valuable as future laboratory studies are performed.
BACKGROUND: Publications using the ALPPS (associating liver partition and portal vein ligation for a staged hepatectomy) procedure have demonstrated a future liver remnant growth of 40-160% in only 6-9 days. The present study aimed to develop and describe the first large animal model of ALPPS that can be used for future studies. METHODS: A total of 13 female domestic pigs underwent ALPPS stage 1 (portal vein division and parenchymal transection) followed by ALPPS stage 2 (completion left-extended hepatectomy) 7 days later. An abdominal computed tomography (CT) scan was performed immediately prior to ALPPS stage 1 surgery and again 7 days later to assess hypertrophy immediately prior to ALPPS stage 2 surgery. Blood samples, as well as tissue analysis for Ki-67, were performed. RESULTS: On CT volumetric analysis, the mean size of the future liver remnant (FLR) prior to ALPPS stage 1 was 21 ± 2% and 40 ± 6% prior to ALPPS stage 2. The median degree of growth was 75% with a mean kinetic growth rate of 11% per day. Liver weights at autopsy correlated well with CT volumetric analysis (r = 0.87). There was no significant difference in mean lab values [asparate aminotransferase (AST), alanine aminotransferase (ALT), ammonia, International Normalized Ratio (INR) or bilirubin] from baseline until immediately prior to ALPPS stage 2. Post ALPPS stage 2 there was a significant increase in INR from baseline 1.1 to 1.6 (P = 0.012). No post-operative deaths secondary to liver failure were observed. CONCLUSION: The present study describes the first reproducible large animal model of the ALPPS procedure. The degree of liver growth and the kinetic rate of growth were similar to that which has been demonstrated in human publications. This model will be valuable as future laboratory studies are performed.
Authors: W T Knoefel; I Gabor; A Rehders; A Alexander; M Krausch; J Schulte am Esch; G Fürst; S A Topp Journal: Br J Surg Date: 2012-11-02 Impact factor: 6.939
Authors: D Pagano; F di Francesco; G J Echeverri; M de Martino; C Ricotta; G Occhipinti; V Pagano; E Oliva; M I Minervini; B G Gridelli; M Spada Journal: Transplant Proc Date: 2012-09 Impact factor: 1.066
Authors: Junichi Shindoh; Mark J Truty; Thomas A Aloia; Steven A Curley; Giuseppe Zimmitti; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Jean-Nicolas Vauthey Journal: J Am Coll Surg Date: 2012-12-07 Impact factor: 6.113
Authors: Christian Wilms; Lars Mueller; Christian Lenk; Oliver Wittkugel; Knut Helmke; Gerrit Krupski-Berdien; Xavier Rogiers; Dieter C Broering Journal: Ann Surg Date: 2008-05 Impact factor: 12.969
Authors: Fernando A Alvarez; Victoria Ardiles; Rodrigo Sanchez Claria; Juan Pekolj; Eduardo de Santibañes Journal: J Gastrointest Surg Date: 2012-11-27 Impact factor: 3.452
Authors: Erik Schadde; Martin Hertl; Stefan Breitenstein; Beatrice Beck-Schimmer; Martin Schläpfer Journal: J Vis Exp Date: 2017-08-14 Impact factor: 1.355
Authors: Harvey S Chen; Dong Jin Joo; Mohammed Shaheen; Yi Li; Yujia Wang; Jian Yang; Clara T Nicolas; Kelly Predmore; Bruce Amiot; Gregory Michalak; Taofic Mounajjed; Jeff Fidler; Walter K Kremers; Scott L Nyberg Journal: Hepatology Date: 2018-12-27 Impact factor: 17.425
Authors: Mariano E Giménez; Eduardo J Houghton; C Federico Davrieux; Edgardo Serra; Patrick Pessaux; Mariano Palermo; Pablo A Acquafresca; Caetano Finger; Bernard Dallemagne; Jacques Marescaux Journal: Arq Bras Cir Dig Date: 2018-03-01
Authors: Henrique de Aguiar Wiederkehr; Julio Cesar Wiederkehr; Luiz Martins Collaço; Eros Luiz de Sousa; Paolo Salvalaggio; Caroline Aragão de Carvalho; Barbara de Aguiar Wiederkehr; Camila Aparecida Moraes Marques; Francielle França da Rosa; Felipe de Negreiros Nanni; Taíse Fuchs Journal: Einstein (Sao Paulo) Date: 2017 Apr-Jun